<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62037">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02298309</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001173/MGH</org_study_id>
    <secondary_id>R21AI110264</secondary_id>
    <nct_id>NCT02298309</nct_id>
  </id_info>
  <brief_title>Test and Treat TB: A Proof of Concept Trial in South Africa</brief_title>
  <acronym>Siyasiza</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Healthcare Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is (1) to establish the feasibility, yield, and clinical impact of
      a &quot;Test &amp; Treat TB&quot; strategy on a mobile HIV screening unit in South Africa and (2) to
      assess the cost and cost-effectiveness of this mobile, integrated HIV/TB screening strategy
      for maximizing linkage to TB care and treatment completion.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Participant</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients who complete tuberculosis treatment</measure>
    <time_frame>9 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of mobile testers screened for tuberculosis</measure>
    <time_frame>16 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of tuberculosis and rifampin resistance</measure>
    <time_frame>16</time_frame>
    <description>The GeneXpert test can detect rifampin resistant strains of tuberculosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of particpants who return to Tester for their tuberculosis test result</measure>
    <time_frame>16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants who link to tuberculosis care, defined as a first visit to a TB treatment site</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who die within 9 months of presenting to the Tester</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Baseline CD4 counts for HIV-infected patients</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HIV-infected partipants who link to HIV care, defined as a first visit to a HIV treatment site</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HIV-infected participants who initiate antiretroviral therapy</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of HIV-infected participants with suppressed HIV viral load</measure>
    <time_frame>9 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4809</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the usual care arm will be screened for tuberculosis (TB) on a mobile unit and referred for treatment according to the current standard of care in South Africa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test-and-Treat Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in the intervention arm will partake in a Test-and-Treat TB strategy involving mobile GeneXpert MTB/RIF testing, facilitated TB treatment initiation, SMS reminders for clinic visits, and cashless incentives.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test-and-Treat TB</intervention_name>
    <arm_group_label>Test-and-Treat Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English or Zulu speaking

          -  presenting for screening at mobile unit

          -  voluntarily undergoing HIV testing

          -  able and willing to give informed consent

          -  willing to share HIV and TB test results

          -  willing to attend one of six local clinics for treatment

          -  access to a mobile phone

        Exclusion Criteria:

          -  pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ingrid V Bassett, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>iThembalabantu Clinic/AIDS Healthcare Foundation</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 21, 2017</lastchanged_date>
  <firstreceived_date>November 18, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Ingrid V. Bassett, MD, MPH</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>TB</keyword>
  <keyword>HIV</keyword>
  <keyword>Test and Treat</keyword>
  <keyword>Linkage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
